Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma.
AffiliationCentre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, Lower Ground Floor, Old Anatomy Building, Charterhouse Square, London, UK
MetadataShow full item record
AbstractTP300, a recently developed synthetic camptothecin analogue, is a highly selective topoisomerase I inhibitor. A phase I study showed good safety and tolerability. As camptothecins have proven active in oesophago-gastric adenocarcinomas, in this phase II study we assessed the efficacy and safety of TP300 in patients with gastric or gastro-oesophageal junction (GOJ) adenocarcinomas.
CitationPhase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma. 2016, 16 (1):779 BMC Cancer